Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
ROCKVILLE, Md., Aug. 02, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant...
-
ROCKVILLE, Md., Aug. 01, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant...
-
Phase I/II clinical trial of RGX-501 for the treatment of homozygous familial hypercholesterolemia is actively recruiting and screening patients; expect to enroll first patient in second half of...
-
ROCKVILLE, Md., May 16, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant...
-
On track to initiate a Phase I/II clinical trial for RGX-501 for the treatment of homozygous familial hypercholesterolemia in the first half of 2016Progressing toward filing an IND with the U.S....
-
ROCKVILLE, Md., May 03, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant...
-
High expression of anti-VEGF antibody achieved in rhesus macaques with administration of RGX-314 for treatment of wet age-related macular degenerationGene transfer mediated by RGX-121 shown to...
-
Entered 2016 in strong financial position with more than $215 million in cash, cash equivalents and marketable securities; on track to advance multiple lead gene therapy product candidate programs...
-
ROCKVILLE, Md., March 01, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant...
-
Company begins 2016 in strong financial position, on track to advance multiple lead gene therapy product candidate programs into clinicRGX-501 IND for treatment of homozygous familial...